Randomized study showing that in type 2 DM patients with high cardiovascular risk, the rate of cardiovascular death, myocardial infarction, or stroke was lower in patients receiving semaglutide than in those receiving placebo
Seus resultados demonstraram uma perda de peso de -15,2% no grupo que tratou com semaglutida versus -2,6% placebo, com 36,1% dos pacientes com perda de peso 20%, de forma segura e sustentada
Campiotto S, Pinho JR, Carrilho FJ, Da Silva LC, Souto FJ, et al
The SELECT trial, which evaluated semaglutide 2.4 mg against placebo for cardiovascular outcomes in patients with overweight and obesity without type 2 diabetes, showed significant decreases in total cholesterol, LDL-C, and triglycerides and an increase in HDL-C at 39.8 months [48]
This landmark study generated the initial excitement around the compound
Hims & Hers utilizes these automated screening layers to ensure that patients meet strict medical criteria for GLP-1 medications while filtering for those who may require alternative treatments